Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer

By afschroeder • November 8, 2025

Lloyd MR, Weipert CM, Ali A, Solomon SR, Saha J, Lipsyc-Sharf MD, Hamilton EP, Kalinsky K, Brufsky AM, Bardia A, Zhang N, Wander SA. Clinical and genomic factors associated with elacestrant outcomes in ESR1-mutant metastatic breast cancer. Clin Cancer Res. 2025 Nov 7. doi: 10.1158/1078-0432.CCR-25-3033. Epub ahead of print. PMID: 41201834.

Tags: Hematology/Oncology, Publications

Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical Trial

Agrawal R, Weiner AB, Livingstone J, Pooli A, Huang RR, Ye H, Sisk A, Elashoff DA, Boutros PC, Rettig MB, Reiter RE. Neoadjuvant Antiandrogen Therapy[...]

Safety and Clinical Outcomes of Pembrolizumab Standard-Interval Dosing Versus Extended-Interval Dosing in Patients with Breast Cancer

LeVee A, Kordic A, Ruel N, Mortimer J, Kang I, McArthur H, Lechner MG, Tsai K. Safety and Clinical Outcomes of Pembrolizumab Standard-Interval Dosing Versus[...]

Molecular Determinants of Immunotherapy Efficacy in Mesothelioma: A Step Toward Precision Oncology

Yang H, Ribas A. Molecular Determinants of Immunotherapy Efficacy in Mesothelioma: A Step Toward Precision Oncology. J Thorac Oncol. 2025 Nov;20(11):1565-1568. doi: 10.1016/j.jtho.2025.08.009. PMID: 41203378.